HOME  |  DIRECTIONS  |  NEWSLETTERS







 

Study TXA 107977
“Trexema”
GlaxoSmithKlein

Enrollment: July1-December 31, 2007

Length of Study: up to 12 months of observation

Medication: Trexema – a combination of sumatriptan (85 mg) and naproxen sodium
(500 mg)

Patient population: adolescents ages 12-17

Rational: Currently, 4-10% of adolescents suffer from migraine, no drugs approved for acute treatment for this age

Primary objective of study: to determine safety and tolerability

Secondary objectives of study: (1) to evaluate the efficacy of the Combination tablet (2) to assess quality of life and productivity before and after use of medication for acute migraine

Design: Open-label, single-arm, multi-center trial

Please call our office and ask for Dr. Latimer if you are interested in having your child be a candidate for our study or email her at Latimer@washingtonheadaches.com Please leave a name and number so that a call can be returned.

 

>Introduction  

Greater Washington Headache Center
1101 30th St., NW | Suite 320 | Washington | DC | 20007
202.625.4898 | 202.625.4899 fax
info@washingtonheadaches.com

Web site design by Marc Nathan and Simply Computers Plus